Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer

被引：67
作者：
Farhat, Fadi S. [2 ]
Tfayli, Arafat [3 ]
Fakhruddin, Najla [5 ]
Mahfouz, Rami [4 ]
Otrock, Zaher K. [3 ]
Alameddine, Raafat S. [3 ,6 ]
Awada, Ahmad H. [1 ]
Shamseddine, Ali [3 ,7 ]
机构：
[1] Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Clin, B-1000 Brussels, Belgium
[2] Hammoud Hosp Univ Med Ctr, Dept Hematol Oncol, Saida, Lebanon
[3] Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon
[4] Amer Univ Beirut, Med Ctr, Dept Pathol & Lab Med, Fac Med, Beirut, Lebanon
[5] Hammoud Hosp Univ Med Ctr, Dept Pathol, Saida, Lebanon
[6] Amer Univ Beirut, Nayef K Basil Canc Ctr, Beirut, Lebanon
[7] Amer Univ Beirut, Div Hematol Oncol, Beirut, Lebanon
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2012年 / 84卷 / 02期
关键词：
Non-small cell lung cancer; VEGF; bFGF; Angiogenic markers; Expression; Prognostic impact; Review; ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; FACTOR MESSENGER-RNA; RANDOMIZED PHASE-II; INCREASED SERUM-LEVELS; TUMOR ANGIOGENESIS; FACTOR-C; CLINICAL-SIGNIFICANCE; LYMPHATIC VESSELS; FACTOR FAMILY;
D O I：
10.1016/j.critrevonc.2012.02.012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Despite major advances in cancer therapeutics, the prognosis for lung cancer patients is still poor and the median survival for patients presenting with advanced non-small cell lung cancer (NSCLC) is only 8-10 months. Angiogenesis is an important biological process and a relatively early event during lung cancer pathogenesis. Anti-angiogenic agents are used in treating patients with NSCLC, and their molecular biomarkers are also being assessed to predict response. A better understanding of the biology of angiogenesis in NSCLC may reveal new targets for treating this malignancy. In this article, we review the expression and prognostic impact of the angiogenic growth factors, vascular endothelial growth factor and basic fibroblast growth factor, in NSCLC. (C) 2012 Published by Elsevier Ireland Ltd.
引用
收藏
页码：149 / 160
页数：12
相关论文
共 119 条
[51]  
Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21387]
[52]  
Joensuu H, 2002, CANCER RES, V62, P5210
[53]   Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer [J].
Johnson, DH ;
Fehrenbacher, L ;
Novotny, WF ;
Herbst, RS ;
Nemunaitis, JJ ;
Jablons, DM ;
Langer, CJ ;
DeVore, RF ;
Gaudreault, J ;
Damico, LA ;
Holmgren, E ;
Kabbinavar, F .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2184-2191
[54]   Proteolytic processing regulates receptor specificity and activity of VEGF-C [J].
Joukov, V ;
Sorsa, T ;
Kumar, V ;
Jeltsch, M ;
ClaessonWelsh, L ;
Cao, YH ;
Saksela, O ;
Kalkkinen, N ;
Alitalo, K .
EMBO JOURNAL, 1997, 16 (13) :3898-3911
[55]   The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients [J].
Kadota, Kyuichi ;
Huang, Cheng-long ;
Liu, Dage ;
Ueno, Masaki ;
Kushida, Yoshio ;
Haba, Reiji ;
Yokomise, Hiroyasu .
EUROPEAN JOURNAL OF CANCER, 2008, 44 (07) :1057-1067
[56]   Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins [J].
Karkkainen, MJ ;
Haiko, P ;
Sainio, K ;
Partanen, J ;
Taipale, J ;
Petrova, TV ;
Jeltsch, M ;
Jackson, DG ;
Talikka, M ;
Rauvala, H ;
Betsholtz, C ;
Alitalo, K .
NATURE IMMUNOLOGY, 2004, 5 (01) :74-80
[57]   The prognostic significance of vascular endothelial growth factor levees in sera of non-small cell lung cancer patients [J].
Kaya, A ;
Ciledag, A ;
Gulbay, BE ;
Poyraz, BM ;
Celik, G ;
Sen, E ;
Savas, H ;
Savas, I .
RESPIRATORY MEDICINE, 2004, 98 (07) :632-636
[58]  
Keith RL, 2000, CLIN CANCER RES, V6, P1616
[59]  
Kido Yasuko, 2001, Kurume Medical Journal, V48, P43
[60]  
Klagsbrun M, 1992, Semin Cancer Biol, V3, P81
12345678910